Adjuvant specific immunotherapy in maintenance treatment of adult acute non-lymphocytic leukemia.

Author: FülleH H, KoeppenK M, RühlH, SchwerdtfegerR

Paper Details 
Original Abstract of the Article :
From 1976 until 1978, 136 adult patients with acute leukemia were treated in four hospitals in Berlin. A complete remission was achieved in 47 patients (35%). Twenty-six patients with non-lymphocytic acute leukemia, who had achieved a complete remission with induction chemotherapy consisting of daun...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1007/BF01721213

データ提供:米国国立医学図書館(NLM)

Evaluating the Efficacy of Immunotherapy in Acute Non-Lymphocytic Leukemia

This study delves into the field of oncology, specifically focusing on the treatment of acute non-lymphocytic leukemia (ANLL), a type of blood cancer. The researchers conducted a randomized clinical trial, a cornerstone of clinical research, to assess the effectiveness of a specific immunotherapy, involving neuraminidase-modified allogeneic blast cells, in conjunction with standard chemotherapy. The aim was to determine if this immunotherapy could improve remission duration and survival in patients with ANLL. The results, however, did not demonstrate a significant benefit of this immunotherapy.

Immunotherapy Shows No Significant Improvement in ANLL Treatment

The study found that the addition of immunotherapy did not lead to a longer duration of remission or improved survival rates in patients with ANLL. While this result may seem discouraging, it provides valuable information for oncologists who are developing new treatment strategies for this challenging disease. The researchers have shed light on the limitations of this particular immunotherapy, paving the way for further research into alternative approaches.

Considerations for ANLL Treatment

While this study indicates the limitations of this specific immunotherapy, the quest for effective treatments for ANLL continues. It is essential to recognize that this research provides valuable insights into the complexities of cancer treatments. As with navigating a desert, the journey to find effective therapies can be challenging and unpredictable. Further research is needed to explore alternative therapies and personalize treatment strategies to improve outcomes for patients with ANLL.

Dr.Camel's Conclusion

This study serves as a reminder that the search for effective therapies in oncology is an ongoing journey. While the results of this trial did not show significant benefits from the investigated immunotherapy, they provide valuable insights into the complexities of ANLL treatment. It is crucial to remain open to new approaches and continue exploring the vast possibilities of immunotherapy research.

Date :
  1. Date Completed 1982-02-22
  2. Date Revised 2019-07-11
Further Info :

Pubmed ID

6947118

DOI: Digital Object Identifier

10.1007/BF01721213

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.